United Therapeutics (UTHR) CEO Rothblatt Buys $1.3M of Stock

Martine Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), purchased 9,500 shares on June 29, 2026, valued at approximately $1.29 million. This acquisition demonstrates a personal investment in the company at an average price of $135.42 per share, coinciding with the stock's price of $538.40 on the publication day.

Rothblatt's purchase adds to her prior activity of acquiring shares of the company. Notably, she made earlier purchases of 9,500 shares on June 25, 2026, and June 22, 2026, each time investing around $1.29 million and $1.32 million, respectively. This consistent buying behavior signals Rothblatt's confidence in the company's future, especially as she has been active in acquiring shares multiple times within a short period.

While there are no reported changes from other institutional investors, it’s worth noting the absence of peers indicating simultaneous trading activity during this time. This singular focus on Rothblatt’s actions highlights her commitment to the company, especially given her role as CEO. The market's reaction to her purchases can also be telling of investor sentiment surrounding United Therapeutics.

The stock has recently been trading near its 52-week high of $609.35, suggesting strong performance in the market. With a P/E ratio of 17.67, the valuation indicates that investors have expectations of future growth, despite a recent revenue decline of about 1.9% year-over-year. As of the last close, the stock was significantly above its 52-week low of $409.07, suggesting a recovery or growth trend.

Analysts Set New Price Targets

Analysts have weighed in on United Therapeutics with varying recommendations. On October 8, 2026, RBC Capital maintained an "Outperform" rating with a price target of $708, up from a previous target of $677. Morgan Stanley also maintained an "Equal-Weight" rating with a target of $566 on October 7, 2026. Meanwhile, BTIG upgraded its stance to "Buy" on October 1, 2026, setting a target of $728. These updates reflect a mixed but generally optimistic sentiment across the analyst community.

Recent Earnings

United Therapeutics is set to report its next earnings on October 28, 2026. The company generated around $3.15 billion in revenue for the last fiscal year, with a net margin of approximately 41.6%. However, analysts will be closely watching for signs of growth or further decline as they prepare for the upcoming earnings report.

Martine Rothblatt's recent share purchases, coupled with the company's strong presence in the healthcare sector, underscore her belief in its future trajectory. United Therapeutics develops innovative therapies for chronic and life-threatening diseases, seeking to meet unmet medical needs in the industry.

What's Next for United Therapeutics Corporation

Looking ahead, investors will be eager to watch for the upcoming earnings report, which may provide further insights into the company's financial health and strategic direction. With Rothblatt’s ongoing purchases and the varied analyst ratings, United Therapeutics remains a point of interest in the healthcare sector. The insights from this report may help clarify the company's future performance and investor sentiment.